RudaCure, une entreprise spécialisée dans le développement de traitements pour les troubles sensoriels, a annoncé that the composé principal development research for RCI002 — actuellement in development as a chronic traitement de la douleur — a été sélectionnée comme supported project under the Korea Drug Development Fund (KDDF) National New Drug Development Program.
The National New Drug Development Program is a cross-ministerial R&D initiative that supports the full lifecycle of développement de nouveaux médicaments sur la base de an open innovation strategy involving entreprises pharmaceutiques, academia, institut de recherches, and hospitals, dans le but de strengthening the global compétitivité of Korea's pharmaceutique and biotechnologie industries and securing pharmaceutique sovereignty as an essential national health requirement.
Grâce à cela program, RudaCure will receive approximately KRW 800 million in R&D funding over two years and will conduct recherche conjointe with the team of Professeur Park Cheol-gyu at Gachon University College of Medicine, the lead institution.
The compound discovered by RudaCure selectively inhibits TRPV1 activity, and in prior research it demonstrated both TRPV1 inhibitory effects and pain reduction in douleur chronique animal models. Unlike existing TRPV1 antagonists, it does not cause abnormal fever, making it expected to stand out as a highly effective analgésique with an excellent safety profile. Optimization research for commercialization will be carried out grâce à cela program.
RudaCure le PDG Yongho Kim a déclaré : "Through recherche conjointe with Professeur Park Cheol-gyu's team at Gachon University College of Medicine, who has extensive research experience in pain, we can break away from the traditionally low-probability développement de médicaments approach and rapidly identify composé principals using computational science methods, which significatifly shortens développement de médicaments time — and this is very exciting."
RudaCure, 'TRPV1 Antagonist' Chronic Pain — "Selected for KDDF Project" (Biospectator)
http://www.biospectator.com/view/news_view.php?varAtcId=17129
Bio startup RudaCure selected for National New Drug Development Program for chronic traitement de la douleur (Medical Today)
https://mdtoday.co.kr/news/view/1065586503001454
Non-narcotic chronic traitement de la douleur selected for National New Drug Development Program (Medipharma)
http://www.medipharmnews.com/news/articleView.html?idxno=112361
Full-scale development of non narcotique 'chronic traitement de la douleur' begins (Herald Economy)
http://news.heraldcorp.com/view.php?ud=20220905000674
RudaCure "Non-narcotic 'chronic traitement de la douleur' selected for National New Drug Development Program project" (Health Korea News)
https://www.hkn24.com/news/articleView.html?idxno=328843
RudaCure, non narcotique 'chronic traitement de la douleur' selected for National New Drug Development Program project (Medigate News)
http://www.medigatenews.com/news/3151924255
RudaCure, non narcotique 'chronic traitement de la douleur' selected for National New Drug Development Program project (Yakup Newspaper)
https://www.yakup.com/news/index.html?mode=view&cat=12&nid=273064
루다큐어 서울연구소